Phase I study of anguidine administered weekly.
Anguidine was administered on a weekly schedule to 20 patients. Gastrointestinal and neurologic toxic effects were dose-limiting for both 4- and 8-hour infusions of anguidine. Myelosuppression was infrequent and not dose-related. Recommended starting doses for weekly anguidine are 6.0 mg/m2 for patients with normal hepatic function and 3.5 mg/m2 for patients with liver dysfunction.
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001853:Bone Marrow / Q000187:drug effects; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009420:Nervous System / Q000187:drug effects; D012717:Sesquiterpenes / Q000627:therapeutic use*; D014255:Trichothecenes / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
D000972:Antineoplastic Agents, Phytogenic; D012717:Sesquiterpenes; D014255:Trichothecenes; C001809:diacetoxyscirpenol